Seaport Therapeutics, Inc. Common Stock (SPTX) Stock Price

SPTXStock
$24.04
Market Cap$1.29B
P/E
PEG Ratio
Div yield
Beta0.21

SPTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)14.87%
VGM Score74.14

SPTX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.66-$1.78-171.19%(-$1.12)
Q1 2026-$3.88-$10.34-166.27%(-$6.46)

SPTX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
4.14
4.33
4.18

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
SPTXSeaport Therapeutics, Inc. Common Stock
B$24.04
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.